Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where B. Del Papa is active.

Publication


Featured researches published by B. Del Papa.


Blood | 2011

Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation

M Di Ianni; Franca Falzetti; Alessandra Carotti; Adelmo Terenzi; F Castellino; Elisabetta Bonifacio; B. Del Papa; Tiziana Zei; Ri Ostini; Debora Cecchini; Teresa Aloisi; Katia Perruccio; Loredana Ruggeri; Chiara Balucani; Antonio Pierini; Paolo Sportoletti; Aristei C; Brunangelo Falini; Yair Reisner; Andrea Velardi; Franco Aversa; Massimo F. Martelli

Hastening posttransplantation immune reconstitution is a key challenge in human leukocyte antigen (HLA)-haploidentical hematopoietic stem-cell transplantation (HSCT). In experimental models of mismatched HSCT, T-regulatory cells (Tregs) when co-infused with conventional T cells (Tcons) favored posttransplantation immune reconstitution and prevented lethal graft-versus-host disease (GVHD). In the present study, we evaluated the impact of early infusion of Tregs, followed by Tcons, on GVHD prevention and immunologic reconstitution in 28 patients with high-risk hematologic malignancies who underwent HLA-haploidentical HSCT. We show for the first time in humans that adoptive transfer of Tregs prevented GVHD in the absence of any posttransplantation immunosuppression, promoted lymphoid reconstitution, improved immunity to opportunistic pathogens, and did not weaken the graft-versus-leukemia effect. This study provides evidence that Tregs are a conserved mechanism in humans.


Clinical and Experimental Immunology | 2009

Immunomagnetic isolation of CD4+CD25+FoxP3+ natural T regulatory lymphocytes for clinical applications.

M Di Ianni; B. Del Papa; Debora Cecchini; Elisabetta Bonifacio; Lorenzo Moretti; Tiziana Zei; R. Iacucci Ostini; Franca Falzetti; L. Fontana; G. Tagliapietra; C. Maldini; Massimo F. Martelli; Antonio Tabilio

Although CD4+/CD25+ T regulatory cells (Tregs) are a potentially powerful tool in bone marrow transplantation, a prerequisite for clinical use is a cell‐separation strategy complying with good manufacturing practice guidelines. We isolated Tregs from standard leukapheresis products using double‐negative selection (anti‐CD8 and anti‐CD19 monoclonal antibodies) followed by positive selection (anti‐CD25 monoclonal antibody). The final cell fraction (CD4+/CD25+) showed a mean purity of 93·6% ± 1·1. Recovery efficiency was 81·52% ± 7·4. The CD4+/CD25+bright cells were 28·4% ± 6·8. The CD4+/CD25+ fraction contained a mean of 51·9% ± 15·1 FoxP3 cells and a mean of 18·9% ± 11·5 CD127 cells. Increased FoxP3 and depleted CD127 mRNAs in CD4+CD25+FoxP3+ cells were in line with flow cytometric results. In Vβ spectratyping the complexity scores of CD4+/CD25+ cells and CD4+/CD25‐ cells were not significantly different, indicating that Tregs had a broad T cell receptor repertoire. The inhibition assay showed that CD4+/CD25+ cells inhibited CD4+/CD25‐ cells in a dose‐dependent manner (mean inhibition percentages: 72·4 ± 8·9 [ratio of T responder (Tresp) to Tregs, 1:2]; 60·8% ± 20·5 (ratio of Tresp to Tregs, 1:1); 25·6 ± 19·6 (ratio of Tresp to Tregs, 1:0·1)). Our study shows that negative/positive Treg selection, performed using the CliniMACS device and reagents, enriches significantly CD4+CD25+FoxP3+ cells endowed with immunosuppressive capacities. The CD4+CD25+FoxP3+ population is a source of natural Treg cells that are depleted of CD8+ and CD4+/CD25‐ reacting clones which are potentially responsible for triggering graft‐versus‐host disease (GvHD). Cells isolated by means of this approach might be used in allogeneic haematopoietic cell transplantation to facilitate engraftment and reduce the incidence and severity of GvHD without abrogating the potential graft‐versus‐tumour effect.


Leukemia | 2014

A revised NOTCH1 mutation frequency still impacts survival while the allele burden predicts early progression in chronic lymphocytic leukemia

Paolo Sportoletti; Stefano Baldoni; B. Del Papa; Patrizia Aureli; Erica Dorillo; Loredana Ruggeri; S Plebani; V Amico; A Di Tommaso; Emanuela Rosati; Pierfrancesco Marconi; M Di Ianni; Franca Falzetti

A revised NOTCH1 mutation frequency still impacts survival while the allele burden predicts early progression in chronic lymphocytic leukemia


Leukemia | 2006

A microelectronic DNA chip detects the V617F JAK-2 mutation in myeloproliferative disorders

M Di Ianni; Lorenzo Moretti; B. Del Papa; Eugenia Gaozza; Alain Sylvin Bell; F Falzetti; Antonio Tabilio

A microelectronic DNA chip detects the V617F JAK-2 mutation in myeloproliferative disorders


Leukemia | 2016

The NOTCH1/CD39 axis: a Treg trip-switch for GvHD.

B. Del Papa; Antonio Pierini; Paolo Sportoletti; Stefano Baldoni; Debora Cecchini; Emanuela Rosati; Erica Dorillo; Patrizia Aureli; Tiziana Zei; R. Iacucci Ostini; Loredana Ruggeri; Alessandra Carotti; Andrea Velardi; R Negrin; Massimo F. Martelli; Franca Falzetti; M Di Ianni

Regulatory T cells (Tregs) suppress alloimmune reaction such as graft versus host disease (GvHD)1 and promote tolerance induction to allogeneic organ transplants.2 In high-risk acute leukaemia patients undergoing full-haplotype mismatched transplantation we demonstrated that adoptive immunotherapy with Tregs conventional T cells (Tcons) almost completely prevented acute and chronic GvHD, favoured post-transplant immunological reconstitution and was associated with a powerful graft-versus-leukaemia (GvL) effect.3, 4, 5 Interestingly, GvHD severity and mortality was markedly reduced by inactivation of NOTCH signalling in donor T cells by means of humanised antibodies and conditional genetic models.6, 7, 8 The present study attempted to unravel the connection between Tregs and NOTCH signalling in Tcons for GvHD prevention. We discovered that NOTCH1 downregulation on Tcons is a new Treg mechanism of action and showed that Tregs use the CD39 pathway to modulate NOTCH1 expression on Tcons.


Leukemia | 2015

Constitutive phosphorylation of the active Notch1 intracellular domain in chronic lymphocytic leukemia cells with NOTCH1 mutation

F. De Falco; Rita Sabatini; Franca Falzetti; M Di Ianni; Paolo Sportoletti; Stefano Baldoni; B. Del Papa; Isabella Screpanti; Pierfrancesco Marconi; Emanuela Rosati

Alterations in Notch signaling are involved in chronic lymphocytic leukemia (CLL) pathogenesis, a hematological disease characterized by the accumulation of CD19+/CD5+ B cells resistant to apoptosis. We previously reported that constitutive Notch1/2 activation contributes to apoptosis resistance of CLL cells.1 Furthermore, a NOTCH1 PEST domain mutation, resulting in a truncated protein more stable and active than wild-type (WT) protein, has recently emerged as a recurrent genetic lesion in CLL patients with adverse prognosis and poor outcome.2, 3 Despite the progress achieved on the role of NOTCH1 mutations in CLL outcome, little is known regarding their role in CLL cell biology. There is evidence that NOTCH1 mutation stabilizes Notch1 signaling in CLL cells,4 but the molecular mechanisms underlying this effect remain to be defined.


Leukemia | 2007

Chronic myeloproliferative disorders: the bone marrow stromal component is not involved in the malignant clone

M Di Ianni; Lorenzo Moretti; B. Del Papa; M. De Ioanni; Elisabetta Bonifacio; Franca Falzetti; Antonio Tabilio

Chronic myeloproliferative disorders: the bone marrow stromal component is not involved in the malignant clone


International Journal of Cancer | 2015

Erratum: γ-Secretase inhibitor I induces apoptosis in chronic lymphocytic leukemia cells by proteasome inhibition, endoplasmic reticulum stress increase and Notch down-regulation (International Journal of Cancer (2013) 132: 8 (1940-1953) DOI: 10.1002/ijc.27863)

Emanuela Rosati; Rita Sabatini; F. De Falco; B. Del Papa; F Falzetti; M Di Ianni; Laura Cavalli; Katia Fettucciari; Andrea Bartoli; Isabella Screpanti; Pierfrancesco Marconi

Rosati E, Sabatini R, De Falco F, Del Papa B, Falzetti F, Di Ianni M, Cavalli L, Fettucciari K, Bartoli A, Screpanti I, Marconi P. gSecretase inhibitor I induces apoptosis in chronic lymphocytic leukemia cells by proteasome inhibition, endoplasmic reticulum stress increase and Notch down-regulation. Int J Cancer. 2013 Apr 15;132(8):1940–1953. doi: 10.1002/ijc.27863. Epub 2012 Oct 17. In this article, Figure 1b contained an error in the plot relative to DMSO treatment at 1 hr. The plot image of DMSO was mistakenly the same plot image relative to GSI treatment at 1 hr, but the gating numbers were correct. The corrected Figure 1b, showing the correct DMSO plot image, is now provided. The authors regret this error, which however, does not alter the conclusions of the study.


Blood Cells Molecules and Diseases | 2004

Mesenchymal cells: a vehicle for gene therapy.

M Di Ianni; B. Del Papa; M. De Ioanni; Paolo Sportoletti; Lorenzo Moretti; Franca Falzetti; Massimo F. Martelli; Antonio Tabilio


Biology of Blood and Marrow Transplantation | 2007

117: Naive and memory T regulatory cells respond to mesenchymal cells regulation

M Di Ianni; B. Del Papa; Debora Cecchini; Lorenzo Moretti; Elisabetta Bonifacio; M. De Ioanni; Federico Bazzucchi; Tiziana Zei; Paolo Sportoletti; Franca Falzetti; Antonio Tabilio

Collaboration


Dive into the B. Del Papa's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge